This work is licensed under the Creative Commons Attribution 4.0 International License.
Lamireau T, Monnereau S, Martin A, Marcotte JE, Winnock M, Alvarez F. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol. 2004; 41:920-5.Search in Google Scholar
Williams SG, Hayller KM, Hodson ME, Westaby D..Prognosis in cystic fibrosis. N Engl J Med. 1992; 327:1244 5.15.Search in Google Scholar
Rowe S.M., Miller S., Sorscher E.J. Mechanisms of disease, Cystic fibrosis. N. Engl. J. Med., 2005; 352:1992-2001.Search in Google Scholar
Guido M, Alves VAF, Balabaud C, Bathal PS, Bioulac-Sage P, Colombari R, et al. Histology of portal vascular changes associated with idiopathic non-cirrhotic portal hypertension: nomenclature and definition. Histopathology. 2019; 74:219–226.Search in Google Scholar
Padoan R, Cirilli N, Falchetti D, Cesana BM. Risk factors for adverse outcome in infancy in meconium ileus cystic fibrosis infants: a multicenter Italian study. J Cystic Fibrosis 2019; 18:863–868. Search in Google Scholar
Wyatt J, Baker H, Prasad P, Gong YY, Millson C. Steatosis and fibrosis in patients with chronic hepatitis C. J Clin Pathol. 2004; 57:402–406.Search in Google Scholar
In ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011; 53:726-36. AST to Platelet Ratio Index (APRI).Search in Google Scholar
Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med. 2013; 158:807-20.Search in Google Scholar
Betapudi B, Aleem A, Kothadia JP. Cystic Fibrosis and Liver Disease. 2022 May 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 32310546.Search in Google Scholar
Jeremy D., Debray D., Beaufrere A., Hillaire S., et al. Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. J Hepatol. 2022; 76(2):420-434.Search in Google Scholar
Lindblad A., Glaumann H., Strandvik B. A Two-Year Prospective Study of the Effect of Ursodeoxycholic Acid on Urinary Bile Acid Excretion and Liver Morphology in Cystic Fibrosis–Associated Liver Disease. Hepatology. 1998; 27(1):166-74.Search in Google Scholar
Nascimento F., Nelson S., Ferreira T., Marques C.D.F., Silva L., Souza E.L. Hepatobiliary disease in children and adolescents with cystic fibrosis. J Pediatr. 2018; 94(5):504---510.Search in Google Scholar
Flass T., Narkewickz M.R. Cirrhosis and other liver disease in cystic fibrosis. Department of Pediatrics University of Colorado School of Medicine and The Pediatric Liver Center, Children’s Hospital Colorado, Aurora, CO, USA, 2012.Search in Google Scholar
Colombo C., Crosignani A., Assaisso M. Battezzati M., Podda M., Giunta A., Zimmer-Nechemias L., Setchell K.D., Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study, Hepatology, 1992; 15; 677-684.Search in Google Scholar
Gobato AO, Vasques ACJ, Ribeiro AF, Yamada RM, Hessel G. Prevalence of hepatic steatosis among children and adolescents with cystic fibrosis and its association with nutritional status, Rev Paul Pediatry 2019; 37:435–441. Search in Google Scholar